Marinus Pharmaceuticals (MRNS) announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV), the Magnolia Study, and oral dose, the Amaryllis Study, in women with postpartum depression (PPD). Based on the positive results, the company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens. Postpartum Depression (PPD) PPD is a mood disorder that affects about …
The Week in Review #4 AMAZING STOCK REBOUNDING - We have already witnessed and wrote about the fierce rebounding of some of our selected stocks comprising: Exelixis (EXEL), Sangamo (SGMO), Array (ARRY), ImmunoGen (IMGN) and others . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Marinus Pharmaceuticals’ (MRNS) stock rallied following its announcement of top-line data from Phase 2 open-label study in patients with the severe epilepsy disorder known as CDKL5. The disease is a rare severe genetic derived epilepsy that results in seizures, pervasive neuro-developmental delay and disabling behavioral issues. The disease has no approved treatments. The good news that boosted the stock price early today has come out …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.